Revenue segments as reported by the company.

Products

Premiums

Services

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit costs

Operating expenses

Goodwill impairment

Store impairments

Opioid litigation charges

Loss on assets held for sale

Restructuring charge

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CVS Health

Aetna is an American managed health care company, which sells traditional and consumer directed health care insurance plans and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans. Aetna is a member of the Fortune 500.

Aetna

CVS Pharmacy is a subsidiary of the American retail and health care company CVS Health, headquartered in Woonsocket, Rhode Island. It was also known as, and originally named the Consumer Value Store and was founded in Lowell, Massachusetts, in 1963. The chain was owned by its original holding company Melville Corporation since its inception until its current parent company CVS Health was spun off into its own company in 1996. CVS Pharmacy is currently the largest pharmacy chain in the United States by number of locations (over 9,600 as of 2016) and total prescription revenue. As the retail pharmacy division of CVS Health, it ranks as the 7th largest U.S. corporation according to Fortune 500 in 2016. CVS Pharmacy's leading competitor Walgreens Boots Alliance ranked 37th.

CVS Pharmacy

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CVS Health exceeds Q4 expectations, eyes growth with Oak Street

CVS Health's strong financial performance in 2022, driven by revenue growth and exceeding EPS expectations, positions the company well for future growth.
The acquisition of Oak Street Health presents opportunities to expand into primary care and improve long-term earnings growth, despite challenges in maintaining retail performance.

CVS Health excels in Q1, eyes growth through acquisitions and innovation

CVS Health's strong financial performance, strategic acquisitions, and customer-centric initiatives position the company for sustained growth and competitive advantage.
While facing challenges in the evolving healthcare landscape, CVS Health's focus on innovation, affordability, and operational efficiency provides a solid foundation for future success.
By capitalizing on opportunities in growth, synergies, and healthcare services, CVS Health can navigate industry headwinds and drive long-term value creation for stakeholders.

CVS Health reports robust Q2 earnings, eyes growth opportunities

CVS Health's Q2 2023 performance reflects strong financial results and strategic acquisitions driving growth.
Despite challenges like higher costs and restructuring charges, the company remains confident in its ability to deliver outstanding performance.
Opportunities lie in expanding Medicaid contracts, biosimilar market establishment, and clinic openings for at-risk populations.
Overall, CVS Health's focus on cost optimization, digital sales growth, and patient engagement positions it well for future success.

CVS Health reports robust Q3 earnings and strategic growth plans

CVS Health's Q3 performance reflects strong financial results and strategic initiatives across its segments, positioning the company for sustainable growth.
While facing challenges like declining vaccine demand and contract losses, CVS Health is focused on leveraging opportunities in biosimilars and cost-saving solutions.
The company's commitment to operational excellence, innovation, and workforce investment underscores its strategic vision for becoming a leading health solutions provider.
With a clear focus on growth drivers and mitigating challenges, CVS Health is poised to capitalize on market opportunities and deliver value to shareholders.

CVS Health reports robust Q4 earnings, eyes Medicare margin recovery

CVS Health's Q4 2023 earnings call highlighted strong financial performance, a cautious stance on Medicare Advantage utilization, and a focus on transforming healthcare delivery. The company is committed to margin recovery, growth, and enhancing customer experience while addressing challenges in Medicare Advantage trends and cost pressures.

CVS Health faces Medicare Advantage challenges, focuses on margin improvement

CVS Health's Q1 2024 earnings call highlighted strong financial performance, challenges in the Medicare Advantage business, and a focus on improving margins. The company showcased strengths in the biosimilar market and Pharmacy & Consumer Wellness segment while addressing issues impacting Health Care Benefits and Services segments.

CVS Health's Q2 2024 performance reflects strong financial results, cost savings, and innovative initiatives in pharmacy services.
The company faces challenges in the Health Care Benefits segment but is actively addressing them through leadership changes and operational improvements.
Opportunities for growth include driving margin improvements, expanding digital reach, and educating stakeholders on the value delivery of PBMs.
Expectation of margin recovery in Medicare Advantage and double-digit EPS growth in 2025 highlight CVS Health's strategic focus on operational efficiencies and cost savings.

CVS Health reports robust Q3 earnings, focuses on growth strategies

CVS Health's Q3 2024 performance was marked by strong financial results, leadership changes, and segment-specific challenges and successes. The company is focused on leveraging opportunities in strategic initiatives and addressing areas for improvement to drive future growth.

Revenue

Cost of revenue

Gross profit

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Walgreens

Walgreens and CVS both sport dividend yields that are more than double the S&P 500 average. Both have been investing significantly in healthcare, which could put pressure on their financials.

CVS Health vs. Walgreens Boots Alliance: Which Is the Better Dividend Stock to Own?

Boston Scientific

WOONSOCKET, R.I. , Sept. 21, 2023 /PRNewswire/ -- CVS Health Corporation (NYSE: CVS) has appointed Michael F.

CVS Health appoints Michael F. Mahoney to its Board of Directors

Awareness of the crisis is widespread, but most Americans lack strong knowledge of the warning signs Despite national trends, Aetna, a CVS Health company, members have seen reductions in suicide-related events over the past year, compared to 2019 baselines WOONSOCKET, R.I. , Sept. 20, 2023 /PRNewswire/ -- A recent CVS Health® (NYSE: CVS)/Harris Poll survey of Americans 18 years and older found that nearly one in five (18%) U.S. adults say they were plagued with suicidal thoughts in the past year.

CVS Health study shows continuing suicide crisis in the U.S.

Medtronic

Income-seeking investors with time before retirement should look for dividend stocks that can rapidly raise their payouts. Medtronic's dividend has risen 38% over the past five years, but its stock price has been beaten down.

2 Beaten-Down Dividend Growth Stocks That Look Like Bargains Now

CVS Health's stock has dropped over 20% since the start of 2023, contrasting with the S&P 500's total return of nearly 18%. Despite the underperformance, we discuss three strong reasons that you should consider adding CVS to your portfolio. Given the company's rock-solid financials, considerable scale, and attractive valuation, now seems like a great time to add this long-term winner to your portfolio.

The Top 3 Reasons To Buy CVS Health

Slow but steady growth is expected to rising prescriptions, aging population, expanded healthcare coverage, and preventive care focus. CVS's scale, market share, and duopoly with Walgreens position it for continued success. CVS cost leadership provides a competitive advantage.

CVS Health Is Undervalued If We Avoid Recession

CVS faces mounting pressure regarding its insurance business, and the stock price has been trending lower in 2023. Shares now trade at an attractive valuation multiple while free cash flow per share is high, but several risks are apparent. Ahead of earnings in early November, I highlight key prices levels to monitor.

CVS Health: Weighing High Free Cash Flow And Bearish Price Trends

CVS stock has not had a good year, underperforming its peers from the healthcare universe by a significant margin. We pick a few green shoots amidst the current gloomy status quo. The market may not be warming up to CVS as yet, but we think the reward to risk equation has tilted to more favorable levels.

CVS Stock: The Risk-Reward Is In A Better Place

Expedia

MGM Resorts

Michael Burry, the legendary investor who famously predicted the 2008 financial crisis, made waves with his recent stock picks again. Burry's insight and strategic thinking led him to invest in three seemingly disparate industries: healthcare, travel, and entertainment.

Betting With the ‘Big Short': 3 Michael Burry Stocks to Bank On

CVS Health's (CVS) updated mRNA COVID-19 vaccine is now available at all its pharmacy locations.

CVS Health's (CVS) New COVID-19 Vaccine Available at Its Stores

AllianceBernstein Hld

Arbor Realty Trust

American Tower

Ares Capital

Alexandria Real Estate Equities

BHP Billiton

British American Tobacco

Discover

Fifth Third Bancorp

Navient

NexPoint Residential Trust

Pfizer

Philip Morris

Taiwan Semiconductor Manufacturing

Vici Properties

March-April, 2022, UBS, Kiplinger, and Barron's listed five sets of stocks sorted as: “Inflation-Busters.” Those five articles revealed 48 equities, with 43 paying dividends. This near 1.5-yr-old list still beats back inflation.

12 Buyable Inflation-Busting September Dividend Stocks

Etsy

CVS Health has a diversified, healthcare-focused business and offers a solid dividend. Etsy is a dominant player in its slice of the large and fast-growing e-commerce sector.

2 Top Stocks to Buy Near Their 52-Week Lows

Charter Communications

Cigna

GEO Group

Generac Holdings

Invesco QQQ

Stellantis N.V. 

Vital Energy Inc

On September 13, Finbold unveiled the latest insights into the enigmatic world of Michael Burry, the renowned ‘Big Short' investor.

Michael Burry's top 10 stock holdings as of September 14

Dollar General

EPAM Systems

U.S. equities markets have had a decent albeit volatile year thus far, as inflation, interest rates, and geopolitical tensions have, at one time or another, weighed on investor sentiment. Let's have a look at the numbers.

3 S&P 500 Stocks to Sell Before a Crash

The US Food and Drug Administration (FDA) has issued warning letters to eight companies including Walgreens Boots Alliance Inc (NASDAQ:WBA) and CVS Health Corp (NYSE:CVS) for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law. The eye products addressed in the eight warning letters are illegally marketed to treat conditions such as conjunctivitis (pink eye), cataracts, glaucoma and others, The FDA said in a news release.

Walgreens and CVS among companies warned by FDA against marketing unapproved eye products

Patients encouraged to consider COVID-19 and flu vaccines in the same visit to ensure optimal protection WOONSOCKET, R.I. , Sept. 13, 2023 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced that the updated COVID-19 vaccine recently authorized by the FDA and recommended by the CDC is now available at its CVS Pharmacy locations.

Updated COVID-19 vaccine now available at CVS Pharmacy®

Amgen

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

These 3 Health Care Stocks With Over 3% Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts - CVS Health (NYSE:CVS), Amgen (NASDAQ:AMGN)

The U.S. Food and Drug Administration (FDA) announced Tuesday that it has sent warning letters to eight companies the agency said are violating federal by manufacturing or marketing unapproved eye treatment products.

CVS, Walgreens Get FDA Warning for Selling Unapproved Eye Drops

CVS Health Corporation (NYSE:CVS ) Morgan Stanley 21st Annual Global Healthcare Conference 2023 September 12, 2023 8:50 AM ET Company Participants Karen Lynch - President, Chief Executive Officer Shawn Guertin - Executive Vice President, Chief Financial Officer Larry McGrath - Senior Vice President, Investor Relations Conference Call Participants Erin Wright - Morgan Stanley Erin Wright Hi. Good morning, everyone.

CVS Health Corporation (CVS) CEO Karen Lynch Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023 (Transcript)

The U.S. Food and Drug Administration this week warned CVS Health Corp. CVS, +2.78%, Walgreens Boots Alliance Inc. WBA, +3.17% and several smaller consumer products companies about marketing unapproved eye products. “The FDA is particularly concerned that these illegally marketed, unapproved ophthalmic drug products pose a heightened risk of harm to users because drugs applied to the eyes bypass some of the body's natural defenses,” the FDA said in a release Tuesday.

FDA warns CVS, Walgreens about marketing of unapproved eye products

The U.S. Food and Drug Administration on Tuesday said it has issued warning letters to eight companies, including pharmacy giants CVS Health Corp and Walgreens Boots Alliance , for manufacturing or marketing unapproved ophthalmic drug products.

FDA issues warning letter to CVS, Walgreens and others for selling unapproved eye products

Apple

Bank of America

Disney

Alphabet

JPMorgan Chase & Co

Morgan Stanley

Microsoft

Seasonal tendencies for the U.S. stock market between now and the end of the year will favor large-cap stocks over small caps.

Why large-cap stocks are a better bet for the rest of 2023 — and 10 you want to own

Archer-Daniels-Midland Company

Dow Inc

Energy Transfer LP Unit

Ford Motor Company

ManpowerGroup

Omnicom Group

Southern Company

Sysco

A Summer 2023 edition of Fortune Magazine revealed 500 biggest U.S. companies by revenue. The quest to sniff-out the best dividend buys focused on 68 industry leaders using YCharts 9/7/23. Those 68 industry leaders were segmented into 21 business sectors ranging (alphabetically) from apparel to transportation. 58 dividend yielding stocks highlighted those 68 industry leaders and ranged 0.15% to 9.05% in annual yield and ranged -65.47% to 45.11% in broker-estimated one-year price-target-upsides by YCharts 9/7/23 reckoning.

4 Ideal Fortune 500 Top September Dividend Dogs

News for CVS Health Stock (CVS)